Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $93.5 million.

  • Gyre Therapeutics' Shares Outstanding (Weighted Average) rose 3.09% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2023 it was $2.5 million, marking a year-over-year increase of 20.64%. This contributed to the annual value of $93.5 million for FY2024, which is 3593.76% up from last year.
  • Per Gyre Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $93.5 million for FY2024, which was up 3,593.76% from $2.5 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) peaked at $93.5 million during FY2024, and registered a low of $1.5 million during FY2020.
  • In the last 3 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) had a median value of $2.5 million in 2023 and averaged $32.7 million.
  • Data for Gyre Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 3,593.76% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Shares Outstanding (Weighted Average) stood at $1.5 million in 2020, then soared by 42.14% to $2.1 million in 2021, then climbed by 0.26% to $2.1 million in 2022, then rose by 20.60% to $2.5 million in 2023, then skyrocketed by 3,593.76% to $93.5 million in 2024.